Lupin Gains USFDA Approval for New Cancer Biosimilar

Lupin gets U.S. FDA nod for biosimilar

The product will be manufactured at the company’s biotech facility in Pune

Lupin gets USFDA nod for biosimilar drug

Lupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at Lupins Pune facility. Armlupeg aims to reduce infection risk from chemotherapy, and Lupin plans to expand its US biosimilar portfolio. The US market for Pegfilgrastim is worth over $1.29 billion annually.

Lupin Gains USFDA Approval for New Cancer Biosimilar

Lupin secures USFDA approval for Armlupeg, a biosimilar indicated for treating neutropenia in cancer patients. The drug, produced at Lupin’s Pune facility, offers a cost-effective alternative to Neulasta. Lupin aims to expand its biosimilar portfolio, enhancing healthcare accessibility in the US market.

Lupin Trades Marginally Higher After USFDA Approval for Armlupeg

Mumbai, December 2 (Udaipur Kiran): Lupin was trading marginally in the green at Rs. 2,087.60 on the BSE, up by 1.25 points or 0.06 per cent from its previous close of Rs. 2,086.35. The stock opened at Rs. 2,101.80 and touched a high of Rs. 2,101.80 and a low of Rs. 2,073.95 during the session. So far, 14,445 shares have been traded on the counter. The BSE Group ‘A’ stock, with a face value of Rs. 2, has touched a 52-week high of Rs. 2,403.45 on…

Neulasta Biosimilar Armlupeg FDA Approved to Prevent Infection

The FDA approved Armlupeg as a biosimilar to Neulasta to reduce infection risk in people receiving chemotherapy and those exposed to radiation.

US FDA approves Lupin’s Armlupeg injection

Lupin has FDA approval for Armlupeg 6mg/0.6ml injection in a single-dose prefilled syringe, for subcutaneous use, as a biosimilar to Neulasta.